Novartis Ag

Bernard Cuenoud

Robin Alec Fairhurst

Ian Bruce

David Beattie

Thomas Hugo Keller

Nicholas Lowther

David Andrew Sandham

Simon James Watson

Gaynor Elizabeth Pilgrim

Pierre Martin

Clive McCarthy

Karl-Heinz Altmann

Roger John Taylor

Heinz Ernst Moser

Emma Budd

Catherine LeBlanc

Neil John Press

Graham Charles Bloomfield

Darren Mark Le Grand

Louise Clare Kirman

Judy Fox Hayler

Katharine Louise Turner

Nicola Press

Mrinalini Sachin Oza

Cathy Ritchie

Ian Francis Hassan

Jeremy Guy Clarke

Barbara Valade

Lewis Whithead

Gaynor Elizabeth Woodward

Reamonn Madden

Compounds of formula in free or salt or solvate form, whereAr is a group of formula Y is carbon or nitrogen and R, R, R, R, R, R, R, R, R, R, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

BETA2-adrenoceptor agonists

Beta2-adrenoreceptor agonists

Compounds of formula in free or salt or solvate form, where 

BETA2-adrenoreceptor agonists

Compounds of formula in free or salt or solvate form, where Ar is a group of formula  Y is carbon or nitrogen and R, R, R, R, R, R, R, R, R, R, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Beta-2-adrenoreceptor agonists

Compounds of formula I in free or salt form, wherein R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Inhibitors of phosphatidylinositol 3-kinase

Compounds of formula I in free or salt form, wherein R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

5-Phenylthiazole derivatives and their use as p13 kinase inhibitors

Compounds of formula I in free or salt form, wherein &#x2014;C&#x2014;Y&#x2014;, Rand Rare G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the &#x3b2;-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Quinoline-2-one derivatives for the treatment of airways diseases

&#x3b2;2-adrenoceptor agonists

A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.

Mixtures or organic compounds for the treatment of airway diseases

Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals

Organic compounds

Compounds of formulain free or salt or solvate form, where

Beta2-adrenoceptor agonists

Growing community of inventors

Horsham, United Kingdom

Bernard Cuenoud